Educated Patient® Breast Cancer Summit at MBCC Keynote Presentation: March 4, 2023
Watch Dr. Anne O'Dea, from University of Kansas Medical Center, discuss targeting ESR1 mutations during the CURE Educated Patient® Breast Cancer Summit at MBCC.
EP: 1.Educated Patient® Breast Cancer Summit at MBCC HER2-Positive Disease Panel: March 4, 2023
EP: 2.Educated Patient® Breast Cancer Summit at MBCC Keynote Presentation: March 4, 2023
EP: 3.Educated Patient® Breast Cancer Summit at MBCC Demystifying Clinical Trials Presentation: March 4, 2023
EP: 4.Educated Patient® Breast Cancer Summit at MBCC Nursing Perspective on Clinical Trials Presentation: March 4, 2023
EP: 5.Educated Patient® Breast Cancer Summit at MBCC Management of Hormone Receptor-Positive Breast Cancer Presentation: March 4, 2023
EP: 6.Educated Patient® Breast Cancer Summit at MBCC Triple-Negative Breast Cancer Treatment Presentation: March 4, 2023
EP: 7.Educated Patient® Breast Cancer Summit at MBCB Hormone Receptor-Positive and TNBC Panel: March 4, 2023
EP: 8.Educated Patient® Breast Cancer Summit at MBCC Genetic Testing Presentation: March 4, 2023
EP: 9.Educated Patient® Breast Cancer Summit at MBCC Circulating Tumor DNA Presentation: March 4, 2023
EP: 10.Educated Patient® Breast Cancer Summit at MBCC Precision Medicine Panel: March 4, 2023
EP: 11.Educated Patient® Breast Cancer Summit at MBCC Radiation Therapy Presentation: March 4, 2023
EP: 12.Educated Patient® Breast Cancer Summit at MBCC De-Escalation of Surgery Presentation: March 4, 2023
EP: 13.Educated Patient® Breast Cancer Summit at MBCC Early-Stage HER2-Positive Presentation: March 4, 2023
EP: 14.Educated Patient® Breast Cancer Summit at MBCC HER2-Positive Metastatic Disease Presentation: March 4, 2023
EP: 15.Educated Patient® Breast Cancer Summit at MBCC Treating Brain Metastases Presentation: March 4, 2023
At the CURE Educated Patient® Breast Cancer Summit, held live and virtually at the Miami Breast Cancer Conference, Dr. Anne O'Dea, medical director of breast cancer survivorship at the University of Kansas Medical Center, presented the keynote lecture, titled “A new era in the treatment of ER+, HER2- Advanced or Metastatic Breast Cancer: targeting ESR1 mutations.”
Educated Patient® Breast Cancer Summit at the Miami Breast Cancer Conference, held March 4, 2023.
In particular, O’Dea discusses the need for new endocrine therapies to treat estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as well as results from the EMERAL trial, that led to the Food and Drug Administration approval of elacestrant (Orserdu) in this patient population.
Disclosure: O’Dea is a consultant and/or speaker for Gilead, DSI, Puma, Pfizer, Novartis and Stemline.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
